Drug
Rdx013
Rdx013: highest development phase Phase 2, developed by Ardelyx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ardelyx
Trials
| Drug | Phase | Indication |
|---|---|---|
| RDX013 NCT04780841 | Phase 2 | Hyperkalemia |
Latest
No recent events.
Follow Rdx013 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.